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Abstract
BACKGROUND: The aim of the study was to achieve an effec-
tive target dose in the thyroid by increasing the effective half-life 
(Teff) of 131I by use of iodide (127I) two days after 131I therapy in 
patients with hyperthyroidism with low Teff. 
MATERIAL AND METHODS: The study was carried out in two 
groups. Group A — 41 patients, and Group B — 14 patients, 
all the patients were with hyperthyroidism with Teff less than 3 
days qualified for 131I therapy. Only group A patients received 
600 μg of iodide a day for 3 days, two days after 131I therapy. 
Radioiodine uptake (RAIU) after 24 and 48 hours, thyroid 
scintiscan and ultrasonography were done before and after 12 
months of 131I therapy. 
RESULTS: In group A a significant increase was seen in the Teff 
(5 days on average) resulting in an increase in the energy target 
dose by 28% and 37%, in patients with Graves’ disease (GD) and 
toxic nodular goitre (TNG), respectively. After one year of therapy 
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50% of GD and 93% of TNG patients achieved euthyroidism; 
28% of GD and 3% of TNG patients were in hypothyroidism. In 
Group B, all the patients had radioiodine treatment failure and 
received a second therapeutic dose of 131I.
CONCLUSIONS: Administration of 127I after 131I treatment can 
lead to an increase in its effective half-life. This will also increase 
the absorbed energy dose in thyroid tissue, thereby improv-
ing therapeutic outcome without administration of a higher or 
second dose of 131I. This may minimize whole-body exposure 
to radiation and reduces the cost of treatment.
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Introduction
Radioiodine therapy (RIT) is considered as the most comfort-
able and economical approach of hyperthyroidism treatment 
caused by Graves’ disease (GD) or toxic nodular goitre (TNG). 
Such treatment is indicated in patients with/or without functional au-
tonomy to normalize thyroid function, and to reduce thyroid volume 
[1, 2]. The outcome of radioiodine (131I) therapy depends mainly on 
the absorbed energy dose in the thyroid tissue [3–5]. The energy 
dose depends on the amount of accumulated radioiodine per 
gram of diseased thyroid tissue. The administered activity can 
be chosen as a standard dose of radioiodine or calculated by 
pre-testing of the 131I kinetics [6]. The rate of iodine turnover in the 
gland is measured by the effective half-life (Teff). Effective half-life 
determination and the uptake of 131I is important for calculating the 
therapeutic dose as the Teff may vary from 1 to 8 days [7] while 
131I uptake ranges from < 10% to > 80%. Turnover of iodine in 
the hyperactive thyroid is often increased for no apparent reason, 
resulting in a reduction of the Teff value. Another variable is the 
local iodine supply of the patient population. 
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The disadvantage of excessively high radioiodine administered 
activities is that the whole body may be exposed to unnecessary 
additional radiation. With lower radioiodine doses there is a risk 
of treatment failure [8]. To minimize such effects it is necessary to 
increase the effective half-life and decrease the therapeutic dose 
of 131I. The administered activity, the resulting target doses in the 
thyroid gland, and the therapeutic outcome depend on the uptake 
of radioiodine. One cause of reduced 131I uptake and shortened 
effective half-life is pre-treatment with ATDs, which may have an ad-
ditional radio-protective effect, or the use of other medication which 
can change radioiodine kinetics; both can influence the outcome 
of 131I therapy [9, 10]. Discontinuation of ATDs starting two or three 
days before 131I therapy is now widely accepted [10]. Another pos-
sible explanation for a short effective 131I half-life during therapy is low 
concentration of iodine in the intra-thyroid pool and the increased 
thyroid hormone secretion in hyperthyroidism. The consequence 
is a rapid turnover of both alimentary iodine and radioiodine 131I. 
Optimal target energy dose in the thyroid can be achieved with 
a high level of 131I uptake and long Teff in the thyroid. An adjunct 
medication for prolongation of the effective half-life is lithium [11, 12] 
and non-radioactive iodine (127I). Lithium is not suitable for routine use 
because of potential side effects and the narrow therapeutic range. 
The effective half-life depends on the iodine supply as well as on T24 
and T48 radioiodine thyroid uptake [13–15] and can be prolonged 
by raising the alimentary iodine supply. Intake of 600 μg of inactive 
iodide orally may increase the levels of iodine in the intra-thyroidal 
pool, making more inactive iodine available for hormone synthesis. 
In consequence, the radioiodine turnover, hormone biosynthesis, and 
release of 131I from thyroid should decrease, all of which lead to pro-
longation of the effective 131I half-life during radioiodine therapy [14].
The aim of the study was to achieve an effective target dose 
in the thyroid by increasing the effective 131I half-life in the thyroid 
by use of 127I two days after 131I therapy in patients with hyperthy-
roidism with low effective half-life.
Material and methods
The study was carried out in two groups of patients treated 
with 131I: Group A and Group B
Group A consisted of 41 patients (32 female and 9 male) with 
hyperthyroidism. There were 14 patients with Graves’ disease and 
27 patients with toxic nodular goitre. Mean age was 57.6 ± 16.9 
years. In all patients the effective half-life was less than 3 days and 
ranged between 1.5 and 2.9 days. 
Group B consisted of 14 patients (10 female and 4 male), 8 of 
them with GD, 6 with TNG. Mean age was 55.8 ± 12.9 years.  In 
all patients the effective half-life was less than 3 days and ranged 
between 1.4 and 2.8 days.
Anti-thyroid drugs were used in patients with overt hyperthy-
roidism to achieve euthyroidism in those with GD and subclinical 
hyperthyroidism in those with TNG. ATDs were discontinued five 
days before 131I treatment. None of the patients had recently 
taken any medication known to affect thyroid function or RAIU. 
Patients had not received iodine-containing agents in the last six 
months. Ophthalmological examination of GD patients excluded 
the presence of active Graves’ ophthalmopathy. 
Before 131I administration all patients underwent clinical ex-
aminations composed of history and physical examinations. All 
patients with GD were in euthyroid state clinically and biochemi-
cally, with serum levels of thyroid-stimulating hormone (TSH) > 0.1 
μIU/ml (normal range 0.2–4.5 μIU/ml), free triiodothyronine (fT3), 
and free thyroxin (fT4) within normal ranges. All patients with TNG 
were in subclinical hyperthyroidism with levels of TSH < 0.1 
μIU/ml, fT3, and fT4 within normal ranges. Fine-needle aspiration 
biopsies were used routinely before radioiodine treatment in all 
patients with dominant nodules within the thyroid gland, to rule 
out malignant changes. Thyroid scan and ultrasonography were 
performed before 131I therapeutic dose administration to assess the 
size of the thyroid nodules and the volume of the thyroid gland. 
In a fasting state all patients underwent a RAIU using 
2 megabecquerels (MBq) of 131I. Thyroid 131I uptake at 24 and 
48 hours was carried out and the results used to calculate di-
agnostic effective half-life (Teff D) (using semi logarithmic paper).
The therapeutic activities of 131I (A in MBq) were calculated 
using Marinelli’s formula [16]:
A (MBq) =
Weight of target thyroid tissue (g) × 
× absorbed dose (Gy) × 24.94
Maximum uptake (%) at time 0 [Tmax] ×
× effective half-life (days)
Two days after 131I therapeutic dose administration, only group 
A patients received 200 μg of inactive potassium iodide (127I) three 
times a day for three days. Afterwards, the therapeutic effective 
half-life (Teff T) was calculated using T120 and T144 RAIU. 
Maximum thyroid uptakes and the effective half-lives of 131I 
were determined after a diagnostic dose (TmaxD) as well as after 
therapeutic dose of 131I (TmaxT) (Figure 1).
Group B patients did not receive inactive potassium iodide.
The 131I was orally administered to the patients as Na131I in 
gelatine capsules. The absorbed dose ranged between 150 and 
300 gray (Gy) for TNG, and 120–200 Gy for GD, and was propor-
tional to thyroid volume. Before radioiodine therapy the thyroid 
gland volume ranged between 20–100 g, measured by thyroid 
Figure 1. Changes of thyroid radioactivity curves after administration 
of radioiodine I131: 1. diagnostic dose (Serie 1, D) and 2. Therapeutic 
dose (Serie 2, T) — 3 days after administration of iodide 600 ug/d 
(from the 3rd to the 5th day of therapy).
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scintigraphy and ultrasound. The used therapeutic activities of 
131I ranged between 200 and 800 MBq. 
In the studied groups, we evaluated:
— thyroid hormones, fT4, and fT3 serum levels — using radio-
immuno assays kits;
— TSH serum levels — by means of immunoradiometric assay 
kits. 
All these parameters were measured before therapy, after 2 
weeks, one month, and monthly, up to 12 months after radioiodine 
therapy.  Thyroid scan and ultrasonography were performed after 
6 and 12 months to assess the influence of RIT on the size of the 
thyroid nodules and the volume of the thyroid gland. 
Statistical analysis using Student’s paired and unpaired t-test 
was performed.
The protocol of the study was approved by the medical ethi-
cal committee of the Medical University of Bialystok, and written 
informed consent was obtained from all participants. The average 
duration of follow-up was 12 months.
Results
The results of thyroid RAIU after ingestion of 127I showed 
a significant increase in the Teff T as a result of the decrease in 
the radioiodine turnover in the thyroid gland. Typical changes in 
decay curves are seen in figure 1. The lowest effective half-life 
(1.5 days) mean of 2.8 ± 0.69 days was observed in patients with 
GD before the RIT. After the 127I administration in all patients there 
was a significant increase in Teff T (5 days on average) result-
ing in 28% and 37% increases in the energy target dose in pa-
tients with Graves’ disease and patients with TNG, respectively. 
Figure 2 shows the average Teff D before and Teff T after 127I 
administration.
In group A — diagnostic effective half-life (3.1 ± 0.65 days) 
was significantly (p < 0.01) shorter than therapeutic effective 
half-life (5.4 ± 0.64 days) (Table 1). Teff D among patients with 
Graves’ disease (2.8 ± 0.69 days) was shorter than in pa-
tients with TNG (3.1 ± 0.62 days). Mean value of Teff T in group 
A was 5.4 ± 0.64 days.
Within Group B, diagnostic effective 131I half-life was shorter 
than Teff D in Group A (2.8 ± 0.61 days). The change of 131I Teff 
D in comparison to Teff T in Group A was statistically significant 
(p < 0.01). 
The mean thyroid volume before RIT amounted to 36.5 ± 25.7 g 
in the whole group and was 36.5 ± 25.7 g in group A, and 
51.7 ± 23.4 g in group B. Results of thyroid ultrasound and thyroid 
scintigraphy after 12 months of 131I therapy showed a significant 
decrease in thyroid volume; 47% on average in patients with GD 
and 40% in patients with TNG (Figure 4 and Table 1). Volume of 
thyroid gland after RIT amounted to 26.2 ± 14.47 g in group A and 
41.4 ± 23.1 g in group B.
The value of T24 was 51.9 ± 13.2% in the whole group; 
51.9 ± 13.2% in group A and 53.2 ± 10.2% in group B. T48 value 
was 39.8 ± 11.6% in group A and 43. 9 ± 9.3% in group B. 
The administered activity was 425.2 ± 195.1 MBq in the whole 
group; 425.2 ± 195.1 MBq in group A and 525.7 ± 168.1 MBq 
in group B (Table 1).
Examples of characteristic thyroid scan of patients with TNG 
and GD, before and after RIT with adjunct use of 127I, are shown 
in Figure 4. 
The average concentrations of fT4 and fT3 were, in general, 
higher in Group A than in Group B. The observed differences were 
statistically significant in both parameters. In group A we observed 
a decrease in serum concentrations of fT3 in both GD and TNG 
patients, after 2, 5, and 6 months of radioiodine therapy in com-
parison to the values in first month of observation (Figure 6). The 
fT4 values were highest in the 3rd month and lowest in the 8th month 
after therapeutic 131I dose administration (Figure 5). Serum TSH 
concentration returned to normal values after five months in most 
of the GD as well as TNG patients (Figure 7). 
In group A, four (28%) out of 14 patients with GD, required oral 
l-thyroxin replacement therapy because of hypothyroidism, seven 
patients (50%) achieved euthyroidism, two patients were in sub-
Table 1. The results of the most important parameters in both 
groups. (X ± SD). There are no statistically significant differences 
between groups
Group A 
(n = 41)
Group B 
(n = 14)
Mean age (years) 57.6 ± 16.9 55.8 ± 12.9  
Duration of hyperthyroidism 5.3 ± 6.5 6.4 ± 2.2
Thyroid volume [ml] 36.5 ± 25.7 51.7 ± 23.4
Thyroid volume [ml] 
(1 year after RIT)
26.2 ± 14.4 41.4 ± 23.1
RAIU T24h% 51.9 ± 13. 2 53.2 ± 10.2
RAIU T48h% 39.8 ± 11.6 43. 9 ± 9.3
131I half-life D1 3.1 ± 0.65 2.8 ± 0.61
131I I half-life D2 5.4 ± 0.64 –
Administered 131I  activity MBq 425.2 ± 195.1 525.7 ± 168.1
Absorption dose Gy 80–300 80–300
Figure 2. The effect of RIT and administration of 600 ug iodide over 3 
days (Group A). (From the 3rd to the 5th day of therapy) on the effective 
half-life in patients with TNG and GD. *statistically significant increase 
compared to pre-therapeutic value.
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clinical hyperthyroidism, and one patient was qualified for another 
dose of radioiodine. One patient (3%) out of 27 patients with TNG 
required oral l-thyroxin replacement therapy because of hypothy-
roidism, 25 patients (93%) were successfully treated and achieved 
euthyroidism, one patient was in subclinical hyperthyroidism, and 
none were qualified for a second dose of 131I.
The administered therapeutic activity of 131I was generally 
smaller in patients receiving 127I, in comparison with patients from 
non-iodide group. Euthyroidism in group A was achieved in 78% 
of patients, hypothyroidism in 12%, and only 9% had subclinical 
hyperthyroidism.
These results, as well as an improvement in the clinical condi-
tion and decrease in goitre size, were observed in all patients of 
group A. 
In Group B, all the patients had radioiodine treatment failure 
and required further radioiodine therapy.
Discussion
Iodine obtained from food is absorbed in the digestive tract 
as iodide (I-). Once in the blood stream, it diffuses rapidly into 
the extracellular space then it follows two principal, competitive 
pathways: uptake by the thyroid gland or excretion in urine. In 
fasting subjects, radioactive tracer is observed in the neck ap-
proximately three minutes after oral administration of 131I [17]. 
Absorption is complete in almost all subjects within a maximum 
of two hours after ingestion. After a single ingestion of radioiodine, 
thyroid uptake begins rapidly and then reaches a plateau at 10% 
to 40% of the total iodine ingested in 24 to 48 hours in euthyroid 
subjects [18]. Uptake varies proportionally to thyroid clearance and 
plasma iodide concentration. Thyroid clearance depends on the 
I
RAIU
T24 = 55.6%
T48 = 42.3%
Tef. = 2.5 d
RAIU
T24 = 30%  
T48 = 28%
Tef = 6.5 d
A B
II
RAIU
T24 = 67.6%
T48 = 51.3%
Tef. = 2.75d
RAIU
T24 = 31%
T48 = 27%
Tef. = 4.75d
C D
Figure 3. Examples of thyroid scans of patients with TNG and GD before and 12 months after RIT. I. Patient with TNG. A. Thyroid scan before RIT. 
B. Thyroid scan 12 months after RIT (600 MBq). II. Patient with GD. C. Thyroid scan before RIT. D. Thyroid scan 12 months after RIT (400 MBq).
Figure 4. The effect of RIT and administration of 600 ug iodide over 
3 days (Group A) (From the 3rd to the 5th day of therapy) on thyroid 
volume (measured 12 months after RIT) in patients with TNG and GD. 
*statistically significant decrease compared to pre-therapeutic volume.
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Figure 5. The behaviour of serum FT3 levels after RIT and administration of 600 ug iodide over 3 days (from the 3rd to the 5th day of therapy)
in patients with TNG and GD.
Figure 6. The behaviour of serum FT4 levels after RIT and administration of 600 ug iodide over 3 days (from the 3rd to the 5th day of therapy) 
in patients with TNG and GD.
volume and function of the gland. It is adaptive and depends on 
plasma iodide concentration and dietary intake. As a result, 
when dietary iodine intake is low, thyroid uptake increases [19, 
20]. During exposure to radioactive iodine, the thyroid absorbed 
dose increases proportionally. Thyroid uptake is higher in ado-
lescents than adults and decreases progressively with age [21]. 
A normally functioning thyroid produces 100 μg levothyroxine and 
10 μg tri-iodothyronine daily, and the intra-thyroidal turnover of 
iodine is estimated at 71.15 μg iodine/d. 
The study of patients with low effective half-life to benefit from 
non-radioactive iodide tablets was based on experimental and 
clinical data [14, 22]. A low iodine diet is thought to be helpful in 
preparing patients for radioiodine therapy [23, 24]. The effects of 
inactive iodide after radioiodine therapy or radioiodine exposure 
are well known. In a retrospective study, Hao et al. [25] described 
298 patients who had received 250 mg iodide daily, beginning 
five days after therapeutic 131I administration. Serum levothyrox-
ine levels and the intra-thyroid 131I washout were lower than in 
patients not receiving additional iodine.
In the treatment of hyperthyroidism, the goal should be to 
minimize the amount of radiation exposed to the patients and to 
the environment, while eliminating the hyperthyroid state. Thyroid 
optimal target energy dose can be achieved by a high uptake and 
long effective half-life of radioiodine in the thyroid.
In the average patient, the effective half-life is often consid-
ered to be five days, which corresponds to a biological half-life 
of 13.2 days. Radiation dose depends not only on uptake but 
also on the effective half-life. For a given uptake, the longer the 
effective half-life, the less radioactive iodine is required to achieve 
a given radiation dose. Because the radiation dose to the thyroid 
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occurs only when radioiodine is present in the thyroid, a larger 
amount of iodine is needed in case of fast turnover. Iodine defi-
ciency can also cause a decrease in the radioiodine retention time 
in the gland. If turnover is slow, the iodine remains in the gland 
for a long time and a smaller amount of radioiodine is needed to 
achieve a given radiation dose. 
Our study was based on the model of iodine metabolism 
published by Urbannek et al. and Dietlein et al. [14, 22, 26]. It 
demonstrates the dependence of effective half-life on the iodine 
supply and on thyroid 131I, and shows that the effective half-life 
could be prolonged by increasing the alimentary iodine supply. 
In our study, the patients with short 131I half-life of less than three 
days benefited from inactive potassium iodide tablet administra-
tion, taken 48 hours after the administration of 131I therapeutic 
activity.
The therapeutic 131I doses given to GD and TNG patients were 
reduced according to the individual increase in the effective half-life 
which led to increased absorbed doses in the thyroid. In our 
study the maximum reduction in thyroid volume was observed at 
12 months. This maximal reduction of thyroid volume was observed 
earlier, at 3–6th months, by others [27, 28].
In group A thyroid RAIU measurement after 127I intake, showed 
an almost 2-fold increase in effective half-life of 131I in the thyroid 
tissue. This can be explained by the rapid hormone synthesis in 
Graves’ hyperthyroidism and TNG, and iodine depletion in the thy-
roid in hyperthyroid patients with TNG and GD due to an emptying 
of the intra-thyroidal iodine pool. This shortens the effective half-life, 
because all the ingested iodine is used for biosynthesis of thyroid 
hormones which are in turn rapidly removed by the increased 
turnover. If the intra-thyroidal iodine pool is filled by increasing the 
iodine supply, the thyroid hormone release remains constant and 
the portion of radioiodine incorporated into thyroid hormones will 
decrease while the effective half-life of 131I in thyroid increases. In 
our study the prolongation of the effective half-life by administration 
of 127I was mostly noted in patients with GD because of intra-thy-
roidal iodine deficiency. In patients with initially short effective 
half-life, the target energy dose was increased by administration 
of 127I , and this led to the use of smaller doses of radioiodine and 
avoidance of further 131I treatment. 
The administered activity of radioiodine was lower in pa-
tients who received inactive iodide (Group A) compared to 
Group B patients. This method was effective, and euthyroidism 
was achieved in most cases, but subclinical hyperthyroidism 
was observed only in 9% of cases. It is worth emphasising that 
in our study after 12 months of radioiodine therapy only 12% of 
patients were in hypothyroidism, which is in contrast to the 100% 
noted in other studies [26].   
In Group B, despite the high doses of radioiodine adminis-
tered, the failure rate was higher and hyperthyroidism persisted in 
all the patients. These unsatisfactory results were due to the low 
effective half-life of 131I.  
Based on the iodine metabolism model, the clinically observed 
increase of the effective 131I half-life by administration of 127I has se-
veral possible explanations: an increase in the intra-thyroidal iodine 
pool, a decrease in thyroid clearance, or a decrease in intra-thyroid 
iodine turnover.
Iodination blockade by use of ATDs is a second possible cause 
of the short 131I half-life [9], but in our group, ATD administration 
was discontinued five days before 131I RAIU test and 131I therapy. 
Therefore, the effects of ATDs were considerably limited in our 
study.
According to the results of several studies [29, 30], thyroid 
uptake can be blocked (at least 95%) by large doses of potassium 
iodide (> 100 mg) administered before, and 5 hours after, the 
radioiodine intake. The administration of 127I prior to radioiodine 
therapy is contraindicated because it would cause an unnecessary 
reduction in radioiodine uptake during therapy.
Conclusions
Administration of non-radioactive iodine two days after 131I 
therapy in patients with hyperthyroidism with short effective half-life 
represent a novelty of the post-therapeutic use of 127I. This can 
cause an increase in 131I effective half-life resulting in an increase 
Figure 7. The behaviour of serum TSH levels after RIT and administration of 600 ug iodide over 3 days (from the 3rd to the 5th day of therapy) 
in patients with TNG and GD.
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in the absorbed energy dose in thyroid tissue, thereby improving 
therapeutic outcome without the necessity of administration of 
a higher or second radioiodine dose. Such a procedure will also 
minimize the whole-body exposure to radiation as well as reduce 
the total cost of therapy. 
This study was supported by a grant from the Medical Uni-
versity of Bialystok 
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